Encouraging interim results for BPH drug

In an interim analysis of efficacy data in a repeat injection study of Nymox's (NYMX +2.8%) investigational drug NX-1207 for benign prostatic hyperplasia (BPH), subjects showed a mean improvement in AUA BPH Symptom Index Score of 8.2 points (n=160). The results compare favorably to the mean improvement of 7.6 points demonstrated in the company's first reinjection trial.

NX-1207 is being evaluated as a treatment for BPH and prostate cancer. It is administered via a transrectal injection that does not require anesthesia or sedation. Patients will undoubtedly prefer a small bore syringe.

Comments (3)
  • gebby
    , contributor
    Comments (1978) | Send Message
    This could be a big drug. Will take time. Little street coverage.
    22 Jul 2014, 02:54 PM Reply Like
  • oldfield
    , contributor
    Comment (1) | Send Message
    After the failure to make Phase 3, is there any residual value to the company?
    12 Nov 2014, 12:26 PM Reply Like
  • truont2
    , contributor
    Comments (4) | Send Message
    This is going to be a big drug if it clears Phase III. Efficacy looks good and convenience for the practitioner/patient makes it a very convincing product. I like the safety profile as well.
    22 Jul 2014, 03:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs